NASDAQHealth CareBiotechnologySnapshot 2026-07-09
Reading AKTS? Create a free portfolio, then add this holding for ongoing Reports and tracking. No credit card.
Create your account →Warn: Management is running behind on a stated commitment.
Aktis plans to start Phase 1b cancer trials in late 2026. It expects early trial data in 2027. The company keeps costs steady despite losses. New science leaders joined to improve research.
Aktis lost $18 million in early 2026 and still has no profit. Revenue is small and growth is uncertain. Clinical trials may not succeed or bring sales soon.
The price is about 21% below our fair value near $35. The market expects continued losses and slow growth. We see potential if trials progress as planned.
Breaks if: Losses grow materially beyond 2026-Q1 levels without revenue growth
Manage operating expenses and cash flow carefully during clinical trial phases to sustain operations.
Newly stated in 2026-Q1. Financials show operating loss of $22.7M and net loss of $18.3M in 2026-Q1, reflecting continued investment in clinical development. No prior quarters provided for comparison, so trajectory is consistent with ongoing clinical-stage spending.
“Operating income was negative $22.7M and net income negative $18.3M in 2026-Q1.”
Breaks if: Trial initiation delayed beyond 2026-Q3 or no data by 2027-Q1
Initiate and progress Phase 1b clinical trials in mCRPC and basket trials for B7-H3 expressing solid tumors in 2026 and 2027.
Newly stated in 2026-Q1. Management disclosed plans to initiate a Phase 1b basket trial in the second half of 2026 and expects preliminary Phase 1b mCRPC clinical trial data in 2027. Financials show revenue of $3.23M and operating loss of $22.7M in 2026-Q1, consistent with early-stage clinical development. The trajectory is early-stage with planned clinical milestones forthcoming.
“Plan to initiate a Phase 1b basket trial in patients with lung, colorectal, and other B7-H3 expressing solid tumors in the second half of 2026.”
Breaks if: Loss of key science leaders or committee disbandment
Enhance board expertise by appointing new directors and forming specialized committees to support science and technology strategy.
Standing thesis, reviewed periodically — not a price target or advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
